Alvotech Announces Completion of FDA Surveillance Inspection at Reykjavik Facility

Alvotech (NASDAQ: ALVO) reported completion of a routine FDA cGMP surveillance inspection at its Reykjavik, Iceland manufacturing facility, ending May 8, 2026, with issuance of a Form 483.

Rhea-AI Summary

Alvotech (NASDAQ: ALVO) reported completion of a routine FDA cGMP surveillance inspection at its Reykjavik, Iceland manufacturing facility, ending May 8, 2026, with issuance of a Form 483.

The company believes observations are addressable, remains on track to resubmit the relevant BLAs in Q2 2026, and continues to expect FDA approvals during 2026.

Positive

• Routine FDA cGMP surveillance inspection at Reykjavik facility completed May 8, 2026
• Company believes Form 483 observations can be addressed quickly
• Alvotech expects to resubmit relevant BLAs in Q2 2026
• Company continues to expect FDA approval of relevant BLAs during 2026
• Outcome viewed as demonstrating strong cGMP fundamentals and site improvements

Negative

• FDA issued a Form 483 with observations for the Reykjavik facility
• FDA approvals for the relevant BLAs are still pending through 2026

Argus May 11 session

+10.12% close to close Open Argus

Details

News Market Reaction – ALVO

On May 11, the day this news came out, ALVO closed 10.12% above the previous close.

Data tracked by StockTitan Argus for the May 11 session.

Market Context

On May 11, the day this news came out, the stock closed 10.1% above the previous close. A strong pos...

Analysis

On May 11, the day this news came out, the stock closed 10.1% above the previous close. A strong positive reaction aligns with the constructive tone of the FDA surveillance inspection outcome. The company reported completion of cGMP review with a Form 483 that it believes is addressable and reaffirmed expectations for 2026 BLA approvals. Past events show shares reacting sharply to earnings and regulatory milestones, so investors could watch how quickly observations are resolved and whether future inspections or filings alter this trajectory.

Key Figures

Inspection end date: May 8, 2026 Expected approval year: 2026

Inspection end date

May 8, 2026

Conclusion of FDA cGMP surveillance inspection at Reykjavik facility

Expected approval year

2026

Company continues to expect FDA approval for relevant BLAs during 2026

Historical Context

5 past events · Latest: May 06

5 events

1. May 06

   Q1 2026 earnings

   24h Move

   -10.4%

   Revenue decline and production slowdowns tied to facility improvements.

2. Apr 30

   Executive change

   24h Move

   +3.6%

   General counsel stepping down and CEO transition arrangements announced.

3. Apr 24

   Earnings date set

   24h Move

   +0.0%

   Scheduled Q1 2026 results release and investor webcast details.

4. Mar 30

   SEC annual filing

   24h Move

   +4.3%

   Form 20-F filed, detailing 2025 results and key risk factors.

5. Mar 30

   Annual report

   24h Move

   +4.3%

   Publication of 2025 Annual Report for investors and stakeholders.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

fda, cGMP, form 483, biologics license applications, +1 more

5 terms

fda regulatory

"the U.S. Food and Drug Administration (FDA) has completed a routine"

The FDA is the U.S. federal agency that evaluates and approves medical drugs, devices, biological therapies and certain foods; think of it as the gatekeeper that decides whether a medical product is safe and effective for patients. For investors, FDA decisions determine whether a company can sell a product, affect expected revenue and introduce regulatory risk, so approvals, rejections or safety warnings can quickly move a company's valuation and stock price.

cGMP regulatory

"completed a routine cGMP surveillance inspection of the company’s"

cGMP (current Good Manufacturing Practice) are government-enforced quality standards that manufacturers must follow to ensure drugs, medical devices, and related products are made consistently, safely, and meet specified quality tests. For investors, cGMP compliance is like a restaurant passing health inspections: it reduces the risk of product recalls, regulatory fines, or production stoppages that can hurt revenue and company value, and it supports market access and long-term trust.

form 483 regulatory

"At the conclusion of the inspection on May 8, 2026, the FDA issued a Form 483."

Form 483 is a written list of inspectional observations issued by the U.S. Food and Drug Administration when inspectors spot potential problems during a facility visit, such as gaps in manufacturing, recordkeeping, or safety controls. For investors it matters because receiving a Form 483 signals possible regulatory trouble that can lead to remediation costs, production delays, product holds or fines—similar to a visible warning sign that a company must fix operations to stay compliant.

biologics license applications regulatory

"positioned to resubmit the relevant Biologics License Applications this quarter"

A biologics license application is a formal request submitted to a regulatory agency to get permission to market a biological medicine—such as vaccines, blood products, or gene and cell therapies—after clinical testing. It’s like applying for a safety and quality permit that lets a company sell a complex medical product; investors watch its progress because approval clears the way for revenue while rejection or delays create significant financial risk.

biosimilar medicines medical

"specializing in the development and manufacture of biosimilar medicines for patients"

Biosimilar medicines are follow‑on versions of complex biological drugs made from living cells that are highly similar to an original approved biologic but not exact copies, like a near‑identical twin rather than a factory‑made duplicate. They matter to investors because they increase competition and typically lower prices for high‑cost therapies, which can reduce revenue for original drugmakers while creating new market opportunities for companies that develop and sell biosimilars.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

- Company remains on track for BLA resubmissions in the second quarter

REYKJAVIK, Iceland, May 11, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announces that the U.S. Food and Drug Administration (FDA) has completed a routine cGMP surveillance inspection of the company’s manufacturing facility in Reykjavik, Iceland.

At the conclusion of the inspection on May 8, 2026, the FDA issued a Form 483. The company believes the observations can be addressed quickly and do not raise any substantial issues with the site or its operations.

Based on the outcome of the inspection, Alvotech is well positioned to resubmit the relevant Biologics License Applications this quarter, once the final data have been compiled.

More importantly, the company believes the outcome of this inspection demonstrates the strong cGMP fundamentals of the site and the robustness of all the improvements the company has implemented since last year.

Alvotech continues to expect FDA approval for the relevant BLAs during 2026.

For further information, contact:

Media
Benedikt Stefansson
Sarah MacLeod
alvotech.media@alvotech.com

Investors
Dr. Balaji V Prasad
Benedikt Stefansson
alvotech.ir@alvotech.com

About Alvotech
Alvotech is a biotechnology company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in biosimilars by delivering high-quality, cost-effective products and services, enabled by a fully integrated approach and broad in-house capabilities. Five biosimilars are already approved and marketed in multiple global markets, including biosimilars to Humira® (adalimumab), Stelara® (ustekinumab), Simponi® (golimumab), Eylea® (aflibercept) and Prolia®/Xgeva® (denosumab). The current development pipeline includes nine disclosed biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Alvotech has formed a network of strategic commercial partnerships to provide global reach and leverage local expertise in markets that include the United States, Europe, Japan, China, and other Asian countries and large parts of South America, Africa and the Middle East. For more information, please visit https://www.alvotech.com. None of the information on the Alvotech website shall be deemed part of this press release.

For more information, please visit our investor portal, and our website or follow us on social media on LinkedIn, Facebook, Instagram and YouTube.

Alvotech Forward Looking Statements
Certain statements in this communication may be considered “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements include, for example, Alvotech’s expectations regarding competitive advantages, business prospects and opportunities including pipeline product development, future plans and intentions, regulatory submissions, review and interactions, the potential approval and commercial launch of its product candidates, the timing of regulatory approval, market launches and financial projections. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Alvotech and its management, are inherently uncertain and are inherently subject to risks, variability, and contingencies, many of which are beyond Alvotech’s control. Factors that may cause actual results to differ materially from current expectations include, but are not limited to factors set forth in the sections entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in documents that Alvotech may from time-to-time file or furnish with the SEC. There may be additional risks that Alvotech does not presently know or that Alvotech currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by an investor as, a guarantee, assurance, prediction or definitive statement of a fact or probability. Alvotech does not undertake any duty to update these forward-looking statements or to inform the recipient of any matters of which any of them becomes aware of which may affect any matter referred to in this communication. Alvotech disclaims any and all liability for any loss or damage (whether foreseeable or not) suffered or incurred by any person or entity as a result of anything contained or omitted from this communication and such liability is expressly disclaimed.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Alvotech (NASDAQ: ALVO) announce on May 11, 2026 about the FDA inspection?

Alvotech announced completion of a routine FDA cGMP surveillance inspection at its Reykjavik facility, which concluded May 8, 2026. According to Alvotech, the FDA issued a Form 483 with observations the company believes are manageable and do not raise substantial concerns about site operations.

Did the FDA issue a Form 483 to Alvotech (ALVO) after the Reykjavik facility inspection?

Yes, the FDA issued a Form 483 following its surveillance inspection of Alvotech’s Reykjavik manufacturing site. According to Alvotech, the company believes the observations can be addressed quickly and that they do not indicate substantial issues with the facility or its operations.

How does the May 2026 FDA inspection affect Alvotech’s BLA resubmissions for ALVO?

Alvotech states it remains on track to resubmit the relevant Biologics License Applications during the second quarter of 2026. According to Alvotech, the inspection outcome positions the company to proceed once final data are compiled, despite the Form 483 observations.

What timeline does Alvotech (ALVO) expect for FDA approval of its BLAs after the May 2026 inspection?

Alvotech continues to expect FDA approval of the relevant BLAs during 2026. According to Alvotech, the completed cGMP surveillance inspection and addressable Form 483 observations support this outlook, assuming successful resubmission and review of the applications.

What does the May 2026 FDA surveillance inspection say about Alvotech’s cGMP compliance?

Alvotech believes the inspection outcome demonstrates strong cGMP fundamentals at its Reykjavik facility and the robustness of improvements implemented since last year. According to Alvotech, the remaining Form 483 observations are not viewed as substantial issues for site operations.

Where is the Alvotech (ALVO) facility inspected by the FDA in May 2026 located?

The FDA’s May 2026 routine cGMP surveillance inspection focused on Alvotech’s manufacturing facility in Reykjavik, Iceland. According to Alvotech, this site develops and manufactures biosimilar medicines intended for patients worldwide and is central to its planned BLA resubmissions.